Arcturus Therapeutics ARCT Stock
Arcturus Therapeutics Price Chart
Arcturus Therapeutics ARCT Financial and Trading Overview
| Arcturus Therapeutics stock price | 15.29 USD |
| Previous Close | 14.73 USD |
| Open | 14.62 USD |
| Bid | 4.43 USD x 200 |
| Ask | 7.96 USD x 200 |
| Day's Range | 14.42 - 15.09 USD |
| 52 Week Range | 5.5 - 24.17 USD |
| Volume | 159.91K USD |
| Avg. Volume | 860.39K USD |
| Market Cap | 428.19M USD |
| Beta (5Y Monthly) | 2.475 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.3 USD |
ARCT Valuation Measures
| Enterprise Value | 250.12M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.169815 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.580275 |
| Price/Book (mrq) | 2.4921422 |
| Enterprise Value/Revenue | 8.517 |
| Enterprise Value/EBITDA | -2.513 |
Trading Information
Arcturus Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.475 |
| 52-Week Change | -18.75% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 24.17 USD |
| 52 Week Low | 5.5 USD |
| 50-Day Moving Average | 9.4 USD |
| 200-Day Moving Average | 7.93 USD |
ARCT Share Statistics
| Avg. Volume (3 month) | 860.39K USD |
| Avg. Daily Volume (10-Days) | 1.05M USD |
| Shares Outstanding | 28.42M |
| Float | 26.15M |
| Short Ratio | 4.55 |
| % Held by Insiders | 7.98% |
| % Held by Institutions | 83.08% |
| Shares Short | 6.1M |
| Short % of Float | 26.68% |
| Short % of Shares Outstanding | 21.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -863.29% |
| Gross Margin | -195.50% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.96% |
| Return on Equity (ttm) | -46.30% |
Income Statement
| Revenue (ttm) | 29.37M USD |
| Revenue Per Share (ttm) | 1.05 USD |
| Quarterly Revenue Growth (yoy) | -89.50% |
| Gross Profit (ttm) | -57415000 USD |
| EBITDA | -99548000 USD |
| Net Income Avi to Common (ttm) | -93276000 USD |
| Diluted EPS (ttm) | -3.33 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 191.48M USD |
| Total Cash Per Share (mrq) | 6.74 USD |
| Total Debt (mrq) | 22.93M USD |
| Total Debt/Equity (mrq) | 13.35 USD |
| Current Ratio (mrq) | 5.879 |
| Book Value Per Share (mrq) | 6.045 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72729000 USD |
| Levered Free Cash Flow (ttm) | 19.26M USD |
Profile of Arcturus Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10285 Science Center Drive |
| ZIP | 92121 |
| Phone | 858 900 2660 |
| Website | https://arcturusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 106 |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Q&A For Arcturus Therapeutics Stock
What is a current ARCT stock price?
Arcturus Therapeutics ARCT stock price today per share is 15.29 USD.
How to purchase Arcturus Therapeutics stock?
You can buy ARCT shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arcturus Therapeutics?
The stock symbol or ticker of Arcturus Therapeutics is ARCT.
Which industry does the Arcturus Therapeutics company belong to?
The Arcturus Therapeutics industry is Biotechnology.
How many shares does Arcturus Therapeutics have in circulation?
The max supply of Arcturus Therapeutics shares is 28.42M.
What is Arcturus Therapeutics Price to Earnings Ratio (PE Ratio)?
Arcturus Therapeutics PE Ratio is now.
What was Arcturus Therapeutics earnings per share over the trailing 12 months (TTM)?
Arcturus Therapeutics EPS is -3.33 USD over the trailing 12 months.
Which sector does the Arcturus Therapeutics company belong to?
The Arcturus Therapeutics sector is Healthcare.
Arcturus Therapeutics ARCT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26186.41 USD — |
-0.56
|
6.24B USD — | 25992.55 USD — | 26329.98 USD — | — - | 6.24B USD — |
|
US Tech Biotechnology
NBI
US
|
6989.76 USD — |
+0.94
|
— — | 6923.95 USD — | 7012.55 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1308.52 USD — |
+1.15
|
— — | 1296.22 USD — | 1310.89 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2212.82 USD — |
-0.16
|
— — | 2197.04 USD — | 2231.45 USD — | — - | — — |
- {{ link.label }} {{link}}
